Therapy of Sporadic and NF2-Related Vestibular Schwannoma.

作者: Longping Yao , Mohammed Alahmari , Yasin Temel , Koos Hovinga

DOI: 10.3390/CANCERS12040835

关键词: Wait and scanVestibular systemMerlin (protein)SchwannomaRadiation therapyDiseaseBrain tumorRadiologyTumor suppressor geneMedicine

摘要: Vestibular schwannoma (VS) is a benign primary brain tumor that occurs sporadic or as part of genetic syndrome. The most common cause the mutation NF2 suppressor gene involved in production protein merlin. Merlin plays role cell growth and adhesion. In patients with NF2, VSs arise bilaterally coincide other tumors. VS, typically unilateral does not combination MRI standard imaging technique can be used to assess size aspect well progression disease. preferred management large VS both types surgery without adjuvant radiation. for medium- small-sized includes wait scan, radiotherapy and/or surgery. This choice depends on preference patient institutional protocols. outcomes surgical treatments are improving due progress equipment/approaches, advances radiation delivery techniques dose optimizations main purpose preserving function long possible control.

参考文章(146)
Miguel Torres‐Martín, Luis Lassaletta, Jose M de Campos, Alberto Isla, Giovanny R Pinto, Rommel R Burbano, Barbara Melendez, Javier S Castresana, Juan A Rey, None, Genome‐wide methylation analysis in vestibular schwannomas shows putative mechanisms of gene expression modulation and global hypomethylation at the HOX gene cluster Genes, Chromosomes and Cancer. ,vol. 54, pp. 197- 209 ,(2015) , 10.1002/GCC.22232
Yashar S. Niknafs, Anthony C. Wang, Khoi D. Than, Arnold B. Etame, B. Gregory Thompson, Stephen E. Sullivan, Hemorrhagic vestibular schwannoma: review of the literature. World Neurosurgery. ,vol. 82, pp. 751- 756 ,(2014) , 10.1016/J.WNEU.2013.02.069
Jose Alonso, Ranald Mackay, Hywel Owen, David Holder, Technologies for delivery of proton and ion beams for radiotherapy International Journal of Modern Physics A. ,vol. 29, pp. 1441002- ,(2014) , 10.1142/S0217751X14410024
T. Strachan, D. Bourn, J. Goodship, D. G R Evans, H. Coakham, S. A. Carter, A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals American Journal of Human Genetics. ,vol. 55, pp. 69- 73 ,(1994)
Takeshi Kino, Hideo Takeshima, Mitsuyoshi Nakao, Toru Nishi, Keizo Yamamoto, Takahiro Kimura, Yoshiki Saito, Masato Kochi, Jun-ichi Kuratsu, Hideyuki Saya, Yukitaka Ushio, Identification of the cis -acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma Genes to Cells. ,vol. 6, pp. 441- 454 ,(2001) , 10.1046/J.1365-2443.2001.00432.X
John G Wolbers, Alof HG Dallenga, Alejandra Mendez Romero, Anne van Linge, What intervention is best practice for vestibular schwannomas? A systematic review of controlled studies BMJ Open. ,vol. 3, pp. 1- 10 ,(2013) , 10.1136/BMJOPEN-2012-001345
D A Moffat, R A Parker, D G Hardy, R Macfarlane, Factors affecting final facial nerve outcome following vestibular schwannoma surgery. Journal of Laryngology and Otology. ,vol. 128, pp. 406- 415 ,(2014) , 10.1017/S0022215114000541
Ruth Diebold, Britta Bartelt-Kirbach, D Gareth Evans, Dieter Kaufmann, C Oliver Hanemann, None, Sensitive Detection of Deletions of One or More Exons in the Neurofibromatosis Type 2 (NF2) Gene by Multiplexed Gene Dosage Polymerase Chain Reaction The Journal of Molecular Diagnostics. ,vol. 7, pp. 97- 104 ,(2005) , 10.1016/S1525-1578(10)60014-1
Gareth R Evans, Simon KW Lloyd, Richard T Ramsden, Neurofibromatosis type 2 Journal of Medical Genetics. ,vol. 37, pp. 897- 904 ,(2000) , 10.1136/JMG.37.12.897
D. A. Moffat, S. K. W. Lloyd, R. Macfarlane, R. Mannion, A. King, S. Rutherford, P. R. Axon, N. Donnelly, S. Freeman, J. R. Tysome, D. G. Evans, R. T. Ramsden, Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. British Journal of Neurosurgery. ,vol. 27, pp. 446- 453 ,(2013) , 10.3109/02688697.2013.771143